Bowen Acquisition에 대한 매도 수량은 투자자에게 Bowen Acquisition의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Bowen Acquisition (NASDAQ:BOWN) 주식, 공매도 수량 보고

Bowen Acquisition Corp is a blank check company.

Bowen Acquisition Corp

Bowen Acquisition Corp - Rights

Interactive Brokers Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 17.27%. Currently, Interactive Brokers Group has a market capitalization of $19.16 billion. 
Buying $1000 In IBKR: If an investor had bought $1000 of IBKR stock 15 years ago, it would be worth $10,916.20 today based on a price of $175.80 for IBKR at the time of writing.
<h3>Interactive Brokers Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742513408_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

IBKR

Here's How Much You Would Have Made Owning Interactive Brokers Group Stock In The Last 15 Years

Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) has outperformed the market over the past 5 years by 2.99% on an annualized basis producing an average annual return of 21.38%. Currently, Ventas has a market capitalization of $29.60 billion. 
Buying $100 In VTR: If an investor had bought $100 of VTR stock 5 years ago, it would be worth $294.39 today based on a price of $67.71 for VTR at the time of writing.
<h3>Ventas's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742512511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Ventas 5 Years Ago Would Be Worth This Much Today

Enterprise Prods Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) has outperformed the market over the past 5 years by 1.27% on an annualized basis producing an average annual return of 19.66%. Currently, Enterprise Prods Partners has a market capitalization of $74.00 billion. 
Buying $1000 In EPD: If an investor had bought $1000 of EPD stock 5 years ago, it would be worth $2,565.84 today based on a price of $34.14 for EPD at the time of writing.
<h3>Enterprise Prods Partners's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742511608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Enterprise Prods Partners 5 Years Ago Would Be Worth Today

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) has outperformed the market over the past 10 years by 3.73% on an annualized basis producing an average annual return of 14.37%. Currently, Guidewire Software has a market capitalization of $16.23 billion. 
Buying $100 In GWRE: If an investor had bought $100 of GWRE stock 10 years ago, it would be worth $375.00 today based on a price of $193.46 for GWRE at the time of writing.
<h3>Guidewire Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742510712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GWRE

Here's How Much You Would Have Made Owning Guidewire Software Stock In The Last 10 Years

Earnings

Citigourp Global Markets 2% Protected Notes Linked To The Djia

CORRECTION: PDD Holdings Q4 2024 Adj EPS $2.76 Misses $19.81 Estimate, Sales $15.15B Miss $115.38B Estimate

Investor jitters about Trump's tariffs and global debt levels are stoking recession fears and driving up<a href="https://www.benzinga.com/markets/commodities/25/01/42759408/gold-prices-to-climb-7-in-2025-amid-trumps-return-to-white-house-and-geopolitical-tensions-momentum-is-taking-back-over"> gold prices</a>. Royal Gold (NASDAQ:<a href="https://www.benzinga.com/quote/RGLD"> RGLD</a>) may be worth a look at if you're an investor who wants to capitalize on the trend. The<a href="https://www.insidermonkey.com/blog/royal-gold-inc-rgld-among-the-best-gold-dividend-stocks-to-buy-according-to-analysts-1468571/"> Insider Monkey</a> website reports over 40 hedge funds are invested in this Royal Gold and there may be more upside. Could this stock be a winner in your portfolio too?&nbsp;
Royal Gold has a simple but profitable business model. It offers financing for mining operations worldwide in exchange for a percentage of the mine's total output. However, the company's name does not encompass the full scope of its operations. Royal Gold also finances various industrial metal operations, including copper, zinc, and silver.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
With that said, it's the gold that has everyone excited. Analysts at some of the world's largest investment banks believe gold prices will continue surging for much of 2025.<a href="https://www.goldmansachs.com/insights/articles/gold-prices-are-forecast-to-rise-another-8-percent-this-year"> Goldman Sachs</a> recently upped its target price for gold from $2,890 to $3,100 per ounce, while JPMorgan's predictions of gold hitting $3,000 per ounce have already come to pass.
Considering that Royal Gold is coming off a strong 2024, those predictions are music to shareholders' ears. The Denver-based company's<a href="https://royalgold.com/investors/financial-reports/default.aspx"> year-end report for 2024</a> featured several impressive results, which included:
<ul>
<li>$332 million in net income &#8211; a 39% increase over the previous year</li>
<li>$719.4 million in revenue &#8211; a 19% increase over the previous year</li>
<li>$529.5 million in operating cash flow &#8211; a 27% increase over the previous year</li>
<li>$346.4 million in adjusted net income ($5.26 per share)</li>
</ul>
The revenue, operating cash flow, and earnings figures are all record totals. Royal Gold also met its upper-end expectations for gold sales, while surpassing expectations for copper and the rest of its portfolio. According to the report, gold sales accounted for 76% of Royal Gold's revenue in 2024. That puts Royal Gold in a great position to profit from the increase in gold prices predicted by <a href="https://www.jpmorgan.com/insights/global-research/outlook/market-outlook">JPMorgan</a> and<a href="https://www.benzinga.com/25/03/44200350/salesforce-ai-expansion-sparks-analyst-optimism-400-price-forecast-set"> Goldman</a>.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
"Our business is designed to deliver leverage to gold, and our 2024 results demonstrate the direct relationship between a strong and rising gold price and Royal Gold&#8217;s financial performance," CEO Bill Heissenbuttel said in the earnings release. "This leverage is evidenced by the impressive percentage increases in operating cash flow and net income, both of which exceeded that of revenue. The foundation of our performance is our diversified portfolio."
Royal Gold's strong 2024 performance was also reflected in its dividend, which increased for the 24th consecutive year. The company announced the 2024 dividend of $1.60 per share will increase to $1.80 in 2025. That's a 12.5% increase and shareholders could get an even bigger payout if gold prices continue to rise as predicted. This stock has the potential to be a strong performer for passive income investors in 2025.
Read Next:
<ul>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>

Personal Finance

Gold Is Surging -- Could Buying This Gold Dividend (RGLD) Stock Be The Best Way To Profit On The Trend?

Streaming giant Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has launched many video games over the years. It has its first MMO coming soon, adding to the company&#8217;s library of games based <a href="https://www.benzinga.com/general/entertainment/24/06/39213738/netflix-reality-show-games-and-chill-streaming-giant-sees-success-from-interactive-games-ba">on its own series </a>and external characters.
What Happened: Netflix recently announced it will launch Spirit Crossing, adding to its lineup of content and exclusives for subscribers<a href="https://www.benzinga.com/general/entertainment/24/11/41821069/netflix-stock-hits-all-time-highs-company-confirms-stranger-things-season-5-for-2025"> later this year.</a>
"Prepare to adventure into a joyful world with Spirit Crossing, a massively cooperative life sim designed to encourage friendship and make the world feel a little less lonely," the company <a href="https://about.netflix.com/en/news/spry-foxs-spirit-crossing-comes-to-netflix-later-this-year">said </a>of the new game.
The game comes from Spry Fox, which Netflix acquired in 2022. The studio has previously released games like Triple Town, Alphabear and Cozy Grove.
Netflix says Spirit Crossing will be the biggest game ever released by Spry Fox.
An MMO, which stands for massively multiplayer online, is an online video game that allows gamers to take part in the same virtual world. Netflix said players will be encouraged to work together with other players to build and decorate their homes and villages, explore the wilderness, follow friends and make new friends to gather resources together.
Interested gamers can<a href="https://playspiritcrossing.com/"> sign up</a> for a closed alpha of the game ahead of its full release.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/01/43114866/netflix-q4-earnings-record-subscribers-nfl-squid-game-push-past-highest-expectations">Netflix Q4 Earnings: Record Subscribers, NFL, &#8216;Squid Game&#8217; Push Past &#8216;Highest Expectations&#8217;</a>
 Why It's Important: Netflix has launched games for years and acquired several gaming companies. This could mark one of the streaming company's most ambitious projects in the gaming space to date.
The launch of an MMO game might keep players interested for longer if done correctly and could provide valuable minutes in game for Netflix's engagement statistics as players customize their world and adventure together.
Cozy games — which are non-violent, emphasizing relaxation — have grown in popularity and Netflix entered the market with a launch from a company that had success in the space. While this game won&#8217;t get as many headlines as its game based on &#8220;Squid Game,&#8221; this could be a storyline to watch for the streamer in 2025.
Since this game isn&#8217;t based on existing Netflix property, the streaming giant has the opportunity to go in reverse order and launch future shows and movies if the game is successful and could also launch consumer products and licensed goods around the game.
Along with announcing Spirit Crossing, Netflix also announced several other upcoming games.
<ul>
<li>The Electric State &#8211; Kid Cosmo: a puzzle game based on the recently released movie "The Electric State" that is available now.</li>
<li>Steel Paws: adventure game from Japanese game developer Yu Suzuki, known for his work on Out Run, Shenmue and Virtua Fighter. The game is scheduled for a March 25 release.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/06/39213738/netflix-reality-show-games-and-chill-streaming-giant-sees-success-from-interactive-games-ba">Netflix Reality Show Games And Chill? Streaming Giant Sees Success From Interactive Games Based On Hit Shows</a></li>
</ul>
Photo: Courtesy Netflix

Entertainment

Gaming

NFLX

Netflix To Launch First MMO Video Game: Is It The Streaming Company's Biggest Gaming Bet Yet?

Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) has outperformed the market over the past 5 years by 8.9% on an annualized basis producing an average annual return of 27.29%. Currently, Hilton Worldwide Holdings has a market capitalization of $55.80 billion. 
Buying $100 In HLT: If an investor had bought $100 of HLT stock 5 years ago, it would be worth $366.19 today based on a price of $231.91 for HLT at the time of writing.
<h3>Hilton Worldwide Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742509807_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Hilton Worldwide Holdings 5 Years Ago Would Be Worth Today

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) has outperformed the market over the past 10 years by 5.39% on an annualized basis producing an average annual return of 16.03%. Currently, Eaton Corp has a market capitalization of $116.74 billion. 
Buying $100 In ETN: If an investor had bought $100 of ETN stock 10 years ago, it would be worth $435.44 today based on a price of $295.40 for ETN at the time of writing.
<h3>Eaton Corp's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742508913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Eaton Corp 10 Years Ago Would Be Worth This Much Today

In the latest quarter, 12 analysts provided ratings for Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Cigna Group, revealing an average target of $366.0, a high estimate of $390.00, and a low estimate of $339.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.16%. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508078_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Cigna Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$365.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$375.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$341.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$390.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$348.00</td>
<td>$394.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$375.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$360.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Raj Kumar</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$379.00</td>
<td>$403.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$339.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$390.00</td>
<td>$420.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cigna Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cigna Group compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Cigna Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Cigna Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cigna Group analyst ratings.</a>
<h2>All You Need to Know About Cigna Group</h2>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.
<h3>Cigna Group: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Cigna Group's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 28.66%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cigna Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.17%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cigna Group's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.43%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Cigna Group's ROA excels beyond industry benchmarks, reaching 0.91%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.78.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Cigna Group Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.9, with a high estimate of $12.00 and a low estimate of $10.00. This current average reflects an increase of 2.83% from the previous average price target of $10.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508065_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Bridge Investment Group among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bridge Investment Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bridge Investment Group compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bridge Investment Group's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Bridge Investment Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BRDG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bridge Investment Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Bridge Investment Group Better</h2>
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The Company operates as one business, a fully integrated real estate investment manager.
<h3>Bridge Investment Group's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Bridge Investment Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.83% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Bridge Investment Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -9.95%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Bridge Investment Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -11.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Bridge Investment Group's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.82%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Bridge Investment Group's debt-to-equity ratio surpasses industry norms, standing at 5.4. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRDG

What Analysts Are Saying About Bridge Investment Group Stock

In the last three months, 7 analysts have published ratings on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $60.0, along with a high estimate of $80.00 and a low estimate of $36.00. A 10.71% drop is evident in the current average compared to the previous average price target of $67.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508047_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Celldex Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celldex Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Celldex Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Celldex Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Celldex Therapeutics</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Financial Insights: Celldex Therapeutics</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Celldex Therapeutics faced challenges, resulting in a decline of approximately -71.56% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Celldex Therapeutics's net margin excels beyond industry benchmarks, reaching -4007.83%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Celldex Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.14%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.83%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDX

7 Analysts Have This To Say About Celldex Therapeutics

7 analysts have shared their evaluations of Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Allegiant Travel, revealing an average target of $94.0, a high estimate of $110.00, and a low estimate of $61.00. Surpassing the previous average price target of $77.14, the current average has increased by 21.86%.
<img src="https://www.benzinga.com/files/images/story/2025/1742508030_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Allegiant Travel among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Ravi Shanker</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$95.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Catherine O'Brien</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Allegiant Travel. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Allegiant Travel compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Allegiant Travel's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Allegiant Travel's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Allegiant Travel analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Allegiant Travel: A Closer Look</h2>
Allegiant Travel Co is a leisure travel company focused on providing travel and leisure services and products to residents of under-served cities in the United States. It operates a low-cost, low utilization passenger airline marketed to leisure travelers in under-served cities, allowing it to sell air transportation both on a stand-alone basis and bundled with the sale of air-related and third-party services and products. In addition, it provides air transportation under fixed-fee flight arrangements. In connection with its leisure travel focus, the company has opened Sunseeker Resort Charlotte Harbor, equipped with several guestrooms and food and beverage outlets. The company's operating segments are the Airline, which generates maximum revenue, and Sunseeker Resort.
<h3>Allegiant Travel: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Allegiant Travel's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 2.73%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Allegiant Travel's net margin excels beyond industry benchmarks, reaching -34.45%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Allegiant Travel's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -18.1%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Allegiant Travel's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.69%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Allegiant Travel's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.97.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGT

Where Allegiant Travel Stands With Analysts

In the preceding three months, 4 analysts have released ratings for Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $82.0, a high estimate of $85.00, and a low estimate of $78.00. Observing a 10.32% increase, the current average has risen from the previous average price target of $74.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508023_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Spire. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Richard Sunderland</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Gabriel Moreen</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Paul Fremont</td>
<td>Ladenburg Thalmann</td>
<td>Announces</td>
<td>Buy</td>
<td>$83.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Spire. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Spire compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Spire's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Spire's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Spire analyst ratings.</a>
<h2>Discovering Spire: A Closer Look</h2>
Spire Inc is a public utility holding company with three reportable business segments: Gas Utility, Gas Marketing and Midstream. The Gas Utility segment includes the regulated operations of Laclede Gas, Alabama Gas Corporation ('Alagasco') changed its name to Spire Alabama Inc. effective September 1, 2017, and Laclede Gas Company changed its name to Spire Missouri Inc. effective August 30, 2017. The Gas Utility segment generates a majority of the company's revenue but is subject to seasonal fluctuations. The Gas Marketing segment includes Laclede Energy Resources, Inc, whose operations include the marketing of natural gas and related activities on a non-regulated basis and the Midstream segment includes transportation and storage of natural gas. Maximum revenue from residential area.
<h3>Key Indicators: Spire's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Spire's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -11.56% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Utilities sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Spire's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.58%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.56%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Spire's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.7%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.59, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Spire's Future

In the latest quarter, 9 analysts provided ratings for Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Blue Owl Capital, presenting an average target of $27.78, a high estimate of $32.00, and a low estimate of $22.00. This current average has increased by 4.01% from the previous average price target of $26.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508016_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Blue Owl Capital's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blue Owl Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Blue Owl Capital compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Blue Owl Capital's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Blue Owl Capital's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OWL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blue Owl Capital analyst ratings.</a>
<h2>Get to Know Blue Owl Capital Better</h2>
Blue Owl Capital Inc is an alternative asset management firm. The company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The company conducts its operations through Blue Owl Capital Holdings LP (Blue Owl Holdings) and Blue Owl Capital Carry LP (Blue Owl Carry). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The company generates substantially all of its revenues in the United States.
<h3>Financial Insights: Blue Owl Capital</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Blue Owl Capital's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.8% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Blue Owl Capital's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 3.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.0%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Blue Owl Capital's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.19%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Blue Owl Capital's debt-to-equity ratio is below the industry average at 1.4, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Blue Owl Capital: 9 Analysts Share Their Views

SS&amp;C Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) has outperformed the market over the past 15 years by 11.72% on an annualized basis producing an average annual return of 22.82%. Currently, SS&amp;C Technologies Hldgs has a market capitalization of $20.39 billion. 
Buying $100 In SSNC: If an investor had bought $100 of SSNC stock 15 years ago, it would be worth $2,184.08 today based on a price of $82.34 for SSNC at the time of writing.
<h3>SS&amp;C Technologies Hldgs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742508012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SSNC

Here's How Much You Would Have Made Owning SS&C Technologies Hldgs Stock In The Last 15 Years

Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.35) by 34.29 percent. This is a 58.18 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $1.24 million which missed the analyst consensus estimate of $1.56 million by 20.83 percent. This is a 19.18 percent decrease over sales of $1.53 million the same period last year.

Earnings Beats

Earnings Misses

ARMP

Armata Pharmaceuticals Q4 2024 GAAP EPS $(0.23) Beats $(0.35) Estimate, Sales $1.24M Miss $1.56M Estimate

Elon Musk and Sen. Ted Cruz (R-Texas) shared some marijuana mirth recently on the latter's podcast, in which they pondered whether smoking weed on the air might boost viewership. "But I was pretty sure it might cause a scandal if we smoked pot," Cruz said.
In an episode of "Verdict with Ted Cruz," the senator said he asked one of the producers prior to the interview, "Should I show up and pull out a joint?" and whether, in doing so, they'd get more views than the time <a href="https://www.benzinga.com/markets/cannabis/18/09/12321478/elon-musk-creates-a-buzz-with-joe-rogan-interview?viewDesktop=1">Musk famously lit up</a> on Joe Rogan's podcast in 2018.
During the Cruz podcast, first <a href="https://www.marijuanamoment.net/elon-musk-and-ted-cruz-joke-about-smoking-marijuana-to-boost-podcast-views/">reported</a> by Marijuana Moment, the senator was discussing his age when <a href="https://www.youtube.com/watch?v=BDREZmpkIz8&amp;t=1537s">Musk piped up</a> that he was born "69 days after April 20," also known as 4/20, the widely celebrated cannabis holiday. Was Musk cleverly mixing a provocative innuendo with a weed reference or just reminding followers not to forget his special day?
<h1 class="wp-block-heading">Those Were The Days My Friends</h1>
Musk, an adamant supporter of President Donald Trump and head of the administration's Department of Government Efficiency (DOGE), now <a href="https://in.benzinga.com/news/legal/25/02/43560520/elon-musk-who-smoked-weed-on-rogans-podcast-calls-federal-drug-testing-a-great-idea">backs mandatory drug testing</a> for federal employees, which could assist his efforts to reduce the federal workforce.
<h1 class="wp-block-heading">Speaking Of Scandals</h1>
Cruz's joke about causing a scandal brought to mind the near meltdown that followed Musk's seemingly carefree on-air smoke session with Rogan.
"I did get a lot of backlash," Musk <a href="https://www.benzinga.com/news/22/08/28369199/elon-musk-says-on-smoking-weed-with-joe-rogan-consequences-for-me-and-spacex-were-actually-not-good">said</a> on a podcast afterward. "I had to have random drug tests and stuff after that to prove that I'm not a drug addict.&#8221;&nbsp;
Musk, CEO of Tesla, said he was drug tested for "everything."&nbsp;
"The consequences for me and SpaceX were actually not good," Musk said then, adding that the entire company had to undergo random drug tests afterward. Not long after, NASA launched an investigation into SpaceX's "culture" and "adherence to a drug-free environment."
<h1 class="wp-block-heading">Cruz And Cannabis? Musk?</h1>
Cruz, meanwhile, is no friend of cannabis, despite his joking. Cruz <a href="https://www.benzinga.com/markets/cannabis/24/05/39007905/ted-cruz-blasts-bidens-cannabis-rescheduling-plan-says-drugged-driving-will-lead-to-car-accident">condemned</a> the Biden administration's <a href="https://www.benzinga.com/markets/cannabis/24/05/38880719/biden-announces-monumental-marijuana-rescheduling-doj-to-take-next-steps">efforts to reclassify cannabis&nbsp;</a>under the&nbsp;<a href="https://www.benzinga.com/topic/controlled-substances-act" target="_blank" rel="noreferrer noopener">Controlled Substances Act</a>&nbsp;(CSA) from Schedule I to Schedule III.
And Musk? Who knows? With 4/20 just one month away, no doubt something will inspire him. We&#8217;ll keep you posted.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44420381/obama-sounds-exactly-like-doge-elon-musk-shares-old-video-of-obamas-2011-campaign-to-cut-waste-announcement-with-joe-biden-at-the-helm">&#8216;Obama Sounds Exactly Like DOGE&#8217;—Elon Musk Shares Old Video Of Obama&#8217;s 2011 &#8216;Campaign To Cut Waste&#8217; Announcement With Joe Biden At The Helm</a></li>
</ul>
Photo: Shutterstock

Cannabis

Government

Politics

Media

Elon Musk, Ted Cruz Joke About Cannabis On Podcast: Should I 'Pull Out A Joint' To Boost Ratings?

The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

ALNY

Alnylam Secures FDA Approval Of sNDA For Its RNAi Therapeutic, AMVUTTRA, For Treatment Of ATTR-CM In Adults To Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations And Urgent Heart Failure Visits

Comments

Bowen Acquisition

매도 수량

Bowen Acquisition (NASDAQ:BOWN) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌